Pfizer and Merck join forces to explore therapeutic potential of anti-PD-1 therapy

[News]

Pfizer Inc. announced today that it has agreed with Merck & Co., Inc., known as MSD outside the United States and Canada ("Merck"), through two Merck subsidiaries, to explore the therapeutic potential of Merck's investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets.

More... (http://www.news-medical.net/news/20140205/Pfizer-and-Merck-join-forces-to-explore-therapeutic-potential-of-anti-PD-1-therapy.aspx)